Advertisement

Picture Demy-Colton BioFuture 2024 NYC 3 Biotech Breakthroughs 650x100px
Collaboration › Details

Lilly–AC Immune: tau aggregation inhibitors, 201812– collab + license agreem CHF80m upfront + CHF1.76b milestones + royalties

 

Period Period 2018-12-12
Organisations Partner, 1st Eli Lilly & Co. Inc. (NYSE: LLY)
  Group Eli Lilly (Group)
  Partner, 2nd AC Immune S.A. (Nasdaq: ACIU)
Products Product ACI-3024 (AC Immune / Lilly)
  Product 2 Morphomer tau aggregation inhibitor
Index term Index term AC Immune–Lilly: credit, 201812 convertible note $50m in connection with license + collab agreement
     

   
Record changed: 2020-03-31

Advertisement

Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x200px

More documents for Eli Lilly (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px




» top